NCT04230304View on ClinicalTrials.gov

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

May 1, 2023

Study Completion Date

October 10, 2027

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Daratumumab

Given IV

DRUG

Ibrutinib

Given PO

Trial Locations (1)

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04230304 - Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | Biotech Hunter | Biotech Hunter